April 14 Merck & Co Inc said the U.S.
Food and Drug Administration on Monday approved its grass pollen
allergy vaccine, Grastek, for patients aged 5 to 65.
The company, which developed the tablet-based drug with
Denmark's ALK Abello, said it expects to launch the
treatment in the United States by late April.
An advisory committee to the U.S. FDA had unanimously
recommended the approval of the drug in December.
The immunotherapy treatment, which got regulatory approval
in Canada in February, has been available in Europe since 2006
under the name Grazax.
Merck's stock closed at $55.57 on Monday on the New York
(Reporting by Natalie Grover in Bangalore; Editing by Savio